Onderwerp · Indicatie
Neuroendocrine tumours
Heterogeneous tumour group with hormone secretion (carcinoid syndrome, VIPomas, insulinomas). Somatostatin analogs are a central therapeutic pillar.
Peptides on this topic
3 peptiden met onderzoek naar dit onderwerpLanreotid
Onderzoek (overig) · 1 studies
Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours.
Relevante waarnemingen
- Humane RCTIn a randomized trial, prolonged progression-free survival in enteropancreatic neuroendocrine tumours (CLARINET).
Octreotide
Onderzoek (overig) · 5 studies
Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours.
Relevante waarnemingen
- Humane RCTReduction in GH and IGF-1 levels in acromegaly patients documented in randomised trials
- Humane RCTReduction in flush-episode frequency and diarrhoea in carcinoid syndrome reported across multiple studies
Pasireotid
Onderzoek (overig) · 1 studies
Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly.
Relevante waarnemingen
- Humane RCTIn a phase 3 trial, lowers cortisol (urinary free cortisol) in Cushing's disease.